Gastroenterology

Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.

Ayah Matar, MD, discusses findings showing elevated serum 7αC4 in SIBO-positive patients, suggesting overlap between SIBO and bile acid diarrhea.

At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.

A randomized trial at 5 Brooklyn FQHCs found mailed FIT kits and navigation raised 6-month screening completion to 35.9% vs 23.6% with usual care.

Eugenia Shmidt, MD, and Zoë Gottlieb, MD, discuss WIsDoM data showing 73% of women with IBD conceived with fertility treatment, most via embryo transfer.

Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.

Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.

Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.

Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.

Smoking was associated with greater odds of EPI, and prevalence ranged from 21.1% to 52.1% depending on the diagnostic test used.

Iliyan D. Iliev, PhD, discusses how fluconazole targets gut Candida to improve disease activity in IBD.

Fluconazole was linked to improved Mayo and Harvey-Bradshaw scores; Iliev outlines the placebo-controlled trial needed next.

Weill Cornell investigator Iliyan D. Iliev, PhD, explains why fluconazole, not nystatin, cleared gut Candida in IBD.

Martin Douglass, PhD, and Vanderbilt colleagues found a Bce module that helps C diff evade bacitracin and host iron restriction

Stay updated with the latest healthcare breakthroughs, including a new ablation catheter for AFib and progress in the hereditary angioedema pipeline.

SPY003 cut histologic disease activity by 10 points at 12 weeks, completing proof-of-concept for Spyre's IBD combinations.

David T. Rubin, MD, on the screening tools, direct questions, and therapy choices behind IBD's three tiers of remission.

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

A gastroenterologist explains why treating bowel inflammation alone isn't enough to call inflammatory bowel disease "controlled."

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.